p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic...

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Loss of the SMARCB1 gene is a key driver for malignant rhabdoid tumors and epithelioid sarcomas.
• SMARCB1 protein is crucial for SWI/SNF chromatin remodeling complexes, regulating gene expression and cell differentiation.

Purpose of the Study:

• To investigate the role of SMARCB1 deficiency and p53 mutations in tumor development using zebrafish models.
• To explore therapeutic strategies for SMARCB1-deficient epithelioid sarcomas by targeting p53-MDM2 interactions.

Main Methods:

• CRISPR-Cas9 gene editing to create germline smarcb1 loss-of-function in zebrafish.
• Induction of tumors by combining smarcb1 deficiency with p53 mutations.
• Testing small molecule inhibitors of the p53-MDM2 interaction and doxorubicin in zebrafish tumor models.

Main Results:

• SMARCB1 deficiency combined with p53 mutation induced epithelioid sarcomas, angiosarcomas, and carcinomas in zebrafish.
• Disruption of p53 was necessary for tumor development in smarcb1-deficient zebrafish, suggesting alternative p53 regulation in human tumors.
• MDM2 inhibition reactivated p53, induced cell-cycle arrest, and apoptosis in epithelioid sarcoma models.
• Combined MDM2 inhibition and doxorubicin showed synergistic effects on epithelioid sarcoma cell viability.

Conclusions:

• SMARCB1 loss and p53 pathway alterations are critical in specific cancer development.
• Targeting the p53-MDM2 interaction offers a potential therapeutic strategy for SMARCB1-deficient epithelioid sarcomas.
• Combined doxorubicin and MDM2 inhibitor therapy warrants further investigation for treating epithelioid sarcoma patients.